You are currently viewing the EU version of the website.

View US version

en

Morphic

First Risk-Benefit Data from the Association of British Clinical Diabetologists (ABCD) Worldwide EndoBarrier Registry

The effects of EndoBarrier therapy on glycaemic control, weight and blood pressure are likely to reduce the complications of type 2 diabetes. This 1st international data from the EndoBarrier worldwide registry suggests that the likely benefits of EndoBarrier treatment, far outweigh the risks.

ADA-2018-Endobarrier-ww-registry-poster.pdf

Privacy Overview
Morphic Medical EU

We respect your privacy. Morphic Medical’s website may collect standard information such as IP address, browser type, and usage statistics to improve your experience. We do not collect sensitive personal data unless you choose to provide it (e.g. via contact forms).

By continuing to use this site, you acknowledge that:

  • We process your data in accordance with the:
    • EU General Data Protection Regulation (GDPR)
    • HIPPA (Health Insurance Portability and Accountability Act)
  • Any data collected is used only for site functionality, security, or user experience improvements
  • You have the right to access, correct, or delete your data at any time

To learn more, view our [Privacy Policy].

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Analytics

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Powered by  GDPR Cookie Compliance